Why is the NIB (ASX:NHF) share price sliding 7% today?

JP Morgan is now bearish on NIB and reckons further downside is imminent.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Downward red arrow with business man sliding down it signifying falling asx share price.

Image source: Getty Images

Key points

  • JP Morgan downgraded NIB to underweight today
  • The broker slashed its price target by 12% to $6.10
  • The firm is cautious on the Australian health insurance sector over the medium to long-term
  • Analysts at the firm like Medibank as a better alternative
  • In the last 12 months the NIB share price has climbed more than 11%

Shares in private health insurer NIB Holdings Limited (ASX: NHF) are plunging more than 7% from the open today and now trade at $6.16 apiece.

Investors are selling the NIB share price today following a broker downgrade from investment bank JP Morgan.

In a note to clients, the broker deconstructs why NIB has fallen out of the limelight, and why it urges its clients to sell the insurer. Let's take a look.

Why's the NIB share price plunging today?

In the absence of any market-sensitive information from the company's camp today, it could be that JP Morgan slashed its price target for NIB by 12% to $6.10.

In doing so, it also assigned an underweight recommendation on the stock, downgrading the insurer from a previous neutral rating.

The broker reckons that insures such as NIB and Medibank Private Ltd (ASX: MPL) have benefitted tremendously from a slowdown in COVID-19 health claims in the short term.

However, it also notes that NIB has made promises that policyholders will see benefits returned to them, which poses a risk to long-term profits.

The broker isn't so rosy on the outlook of the Australian health insurance sector over the medium to long-term, noting widening capital requirements, lower rate increases and headwinds to profits in some business lines.

Specifically, the investment bank alludes to NIB's Australian Residents Health Insurance unit that appears to be struggling based on the numbers.

JP Morgan reckons that NIB will overreach its margin targets in this segment once again, especially due to its stance on retaining COVID-19 benefits for shareholders.

Analysts at the firm like Medibank as a better alternative, although the team also downgraded its view on NIB's rival to underweight as well today.

Shares have faltered after the broker released its scathing cross-examination on NIB, and are now trading at their lowest level in almost 6 months.

As seen on the chart below, both shares have tracked each other fairly closely over the last 12 months, with the exception of NIB's breakout-correction phase in August last year.

TradingView Chart

Hence, it appears we might be at a crossroads between the pair and the next course of direction in their share prices.

NIB share price snapshot

In the last 12 months, the NIB share price has climbed more than 11%. Since January 1 this year however, it has slipped well into the red and is 12% down.

Not only that, but in the last week of trading, shares have fallen another 6% amid a market-wide selloff that's been in situ since December last year.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended NIB Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes

Person with thumbs down and a red sad face poster covering their face.
Broker Notes

6 ASX 200 shares downgraded by the experts this week

Brokers have reduced their ratings on six ASX 200 shares, including PLS Group and Westpac this week.

Read more »

Sell buy and hold on a digital screen with a man pointing at the sell square.
Broker Notes

Should you buy Wesfarmers shares amid rising profits and revenues?

A leading analyst offers his outlook for Wesfarmers shares.

Read more »

A man sits in deep thought with a pen held to his lips as he ponders his computer screen with a laptop open next to him on his desk in a home office environment.
Broker Notes

Buy, hold, sell: Evolution Mining, Netwealth, and Nufarm shares

What is Morgans saying about these popular shares? Let's dig deeper into things.

Read more »

Health professional looking at a laptop.
Broker Notes

Is the Telix share price heading to $19? This broker thinks it is

Bell Potter remains bullish on this name. Here's what it is saying.

Read more »

Happy man working on his laptop.
Broker Notes

Broker says this ASX 200 stock can deliver a 20% return

Bell Potter is bullish on this fintech stock. Let's see what is saying about this one.

Read more »

A man holding a cup of coffee puts his thumb up and smiles with a laptop open.
Broker Notes

ASX 200 shares with renewed buy ratings this week

Brokers have signalled ongoing confidence in Zip, ANZ, Coles, and several other ASX 200 shares.

Read more »

Comical investor reading documents and surrounded by calculators.
Broker Notes

4 ASX 200 shares newly upgraded this week

As the Iran war and fuel crisis continues, some ASX 200 shares have attracted upgrades from the experts.

Read more »

A smiling woman puts fuel into her car at a petrol pump.
Broker Notes

Up 60% in a year, 3 reasons to buy Ampol shares today

A leading analyst forecasts more outperformance from Ampol’s surging shares. But why?

Read more »